6 results on '"Honce JM"'
Search Results
2. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
- Author
-
Sakamoto MR, Honce JM, Lindquist DL, and Camidge DR
- Subjects
- Adult, Aminopyridines, Anaplastic Lymphoma Kinase antagonists & inhibitors, Central Nervous System drug effects, Drug Approval, Humans, Lactams, Male, Neoplasm Metastasis, Pyrazoles, Recurrence, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Central Nervous System pathology, Crizotinib therapeutic use, Lactams, Macrocyclic therapeutic use, Lung Neoplasms drug therapy, Organophosphorus Compounds therapeutic use, Pyrimidines therapeutic use
- Published
- 2019
- Full Text
- View/download PDF
3. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
- Author
-
Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, and Alvarez E
- Subjects
- Adult, Contrast Media, Drug Administration Schedule, Female, Gadolinium, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Retrospective Studies, Survival Analysis, Time Factors, Treatment Outcome, Fingolimod Hydrochloride administration & dosage, Immunologic Factors administration & dosage, Multiple Sclerosis diagnostic imaging, Multiple Sclerosis drug therapy, Natalizumab administration & dosage
- Abstract
Background: Due to the recurrence of disease activity in multiple sclerosis (MS) patients, a washout period of <3 months has been suggested for the transition from natalizumab (NTZ) to fingolimod (FTY). However, very short transition periods of <1 month may be more beneficial., Methods: Retrospective analysis of patients from the Rocky Mountain MS Center at the University of Colorado who were: a) on NTZ for ≥6 months prior to switching to FTY; b) had a transition period ≤ 6 months; and c) initiated FTY treatment prior to November 2013. Transition periods were grouped as follows: <1 month, 1-2 months, and 3-6 months. Outcomes assessed include clinical and MRI measures within one year of FTY initiation., Results: Thirty-seven, 56 and 24 patients had a transition period < 1 month, 1-2 months and 3-6 months, respectively. Baseline characteristics were well matched: mean age 45-49 years (p = 0.17), disease duration 11-13 years (p = 0.42), and ~70% women (p = 1.00). Following the switch (including transition period), clinical relapses were observed in 0% (<1 month), 12.5% (1-2 months), 37.5% (3-6 month) (p < 0.001) of patients. New gadolinium enhancing lesions occurred in 3.3% (<1 month), 13% (1-2 months), 21.4% (3-6 months) (p = 0.13) patients. New T2 lesions were observed in 11.1% (<1 month), 16.3% (1-2 months), 33.3% (3-6 months) (p = 0.28) of patients. There were no unexpected adverse events or PML observed., Conclusions: Minimizing transition times from NTZ to FTY was beneficial and safe., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
4. Isolated focal dystonia phenotypes are associated with distinct patterns of altered microstructure.
- Author
-
Berman BD, Honce JM, Shelton E, Sillau SH, and Nagae LM
- Subjects
- Aged, Diffusion Tensor Imaging, Female, Humans, Male, Middle Aged, Basal Ganglia diagnostic imaging, Blepharospasm diagnostic imaging, Cerebellum diagnostic imaging, Torticollis diagnostic imaging
- Abstract
Objective: Isolated adult-onset focal dystonia is considered a network disorder with disturbances to the motor basal ganglia and cerebellar circuits playing a pathophysiological role, but why specific body regions become affected remains unknown. We aimed to use diffusion tensor imaging to determine if the two most common phenotypes of focal dystonia are associated with distinguishing microstructural changes affecting the motor network., Methods: Fifteen blepharospasm patients, 20 cervical dystonia patients, and 30 age- and sex-matched healthy controls were recruited. Maps of fractional anisotropy and mean diffusivity were analyzed using a voxel-based approach and an automated region-of-interest technique to evaluate deep gray matter nuclei. Correlations between diffusion measures and dystonia severity were tested, and post hoc discriminant analyses were conducted., Results: Voxel-based analyses revealed significantly reduced fractional anisotropy in the right cerebellum and increased mean diffusivity in the left caudate of cervical dystonia patients compared to controls, as well as lower fractional anisotropy in the right cerebellum in cervical dystonia patients relative to blepharospasm patients. In addition to reduced fractional anisotropy in the bilateral caudate nucleus of cervical dystonia patients relative to controls and blepharospasm patients, region-of-interest analyses revealed significantly reduced fractional anisotropy in the right globus pallidus internus and left red nucleus of blepharospasm patients compared to both controls and cervical dystonia patients. Diffusivity measures in the red nucleus of blepharospasm patients correlated with disease severity. In a three-group discriminant analysis, participants were correctly classified with only modest reliability (67-75%), but in a two-group discriminant analysis, patients could be distinguished from each other with high reliability (83-100%)., Conclusions: Different focal dystonia phenotypes are associated with distinct patterns of altered microstructure within constituent regions of basal ganglia and cerebellar circuits.
- Published
- 2018
- Full Text
- View/download PDF
5. Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation.
- Author
-
Kindred JH, Li K, Ketelhut NB, Proessl F, Fling BW, Honce JM, Shaffer WR, and Rudroff T
- Subjects
- Adult, Affect drug effects, Aged, Disabled Persons, Fatigue etiology, Fatigue prevention & control, Female, Humans, Internet, Male, Marijuana Smoking, Medical Marijuana pharmacology, Memory drug effects, Memory Disorders etiology, Memory Disorders prevention & control, Middle Aged, Mood Disorders etiology, Mood Disorders prevention & control, Multiple Sclerosis complications, Obesity etiology, Obesity prevention & control, Parkinson Disease complications, Surveys and Questionnaires, Cannabis, Medical Marijuana therapeutic use, Multiple Sclerosis drug therapy, Parkinson Disease drug therapy
- Abstract
Objectives: Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson's disease (PD) and Multiple Sclerosis (MS) are mostly unknown. Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users., Methods: An anonymous web-based survey was hosted on the Michael J. Fox Foundation and the National Multiple Sclerosis Society webpages from 15 February to 15 October 2016. The survey collected demographic and cannabis use information, and used standardized questionnaires to assess neurological function, fatigue, balance, and physical activity participation. Analysis of variance and chi-square tests were used for the analysis., Results: The survey was viewed 801 times, and 595 participants were in the final data set. Seventy-six percent and 24% of the respondents reported PD and MS respectively. Current users reported high efficacy of cannabis, 6.4 (SD 1.8) on a scale from 0 to 7 and 59% reported reducing prescription medication since beginning cannabis use. Current cannabis users were younger and less likely to be classified as obese (P < 0.035). Cannabis users reported lower levels of disability, specifically in domains of mood, memory, and fatigue (P<0.040)., Conclusions: Cannabis may have positive impacts on mood, memory, fatigue, and obesity status in people with PD and MS. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
6. Diagnostic, treatment, and surgical imaging in epilepsy.
- Author
-
Nagae LM, Lall N, Dahmoush H, Nyberg E, Mirsky D, Drees C, and Honce JM
- Subjects
- Epilepsy therapy, Humans, Magnetic Resonance Imaging standards, Neurosurgical Procedures methods, Tomography, Emission-Computed, Single-Photon methods, Epilepsy diagnostic imaging, Magnetic Resonance Imaging methods
- Abstract
Dedicated epilepsy centers are growing in hospitals throughout the USA and abroad, with a continuously increasing role of imaging in multidisciplinary meetings. Imaging is paramount in diagnosis, treatment, and surgical decision-making in lesional and nonlesional epileptic disease. Besides being up-to-date with technical developments in imaging that may make an impact in patient care, familiarity with clinical and surgical aspects of epilepsy is fundamental to better understanding of patient management. The present article intends to revisit diagnostic, therapeutic, and surgical imaging in epilepsy. Finally, with the increase in frequency of epilepsy management-related procedures and their hardware, MRI safety issues are discussed., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.